BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Camporesi E, Nilsson J, Brinkmalm A, Becker B, Ashton NJ, Blennow K, Zetterberg H. Fluid Biomarkers for Synaptic Dysfunction and Loss. Biomark Insights 2020;15:1177271920950319. [PMID: 32913390 DOI: 10.1177/1177271920950319] [Cited by in Crossref: 33] [Cited by in F6Publishing: 38] [Article Influence: 16.5] [Reference Citation Analysis]
Number Citing Articles
1 Gómez de San José N, Goossens J, Al Shweiki MR, Halbgebauer S, Oeckl P, Steinacker P, Danzer KM, Graf H, Schönfeldt-lecuona C, Belbin O, Lleó A, Vanmechelen E, Otto M. Glutamate receptor 4 as a fluid biomarker for the diagnosis of psychiatric disorders. Journal of Psychiatric Research 2022;156:390-397. [DOI: 10.1016/j.jpsychires.2022.10.010] [Reference Citation Analysis]
2 Vrillon A, Mouton-liger F, Martinet M, Cognat E, Hourregue C, Dumurgier J, Bouaziz-amar E, Brinkmalm A, Blennow K, Zetterberg H, Hugon J, Paquet C. Plasma neuregulin 1 as a synaptic biomarker in Alzheimer’s disease: a discovery cohort study. Alz Res Therapy 2022;14:71. [DOI: 10.1186/s13195-022-01014-7] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
3 Nilsson J, Ashton NJ, Benedet AL, Montoliu-gaya L, Gobom J, Pascoal TA, Chamoun M, Portelius E, Jeromin A, Mendes M, Zetterberg H, Rosa-neto P, Brinkmalm A, Blennow K. Quantification of SNAP-25 with mass spectrometry and Simoa: a method comparison in Alzheimer’s disease. Alz Res Therapy 2022;14:78. [DOI: 10.1186/s13195-022-01021-8] [Reference Citation Analysis]
4 Qiang Q, Skudder-Hill L, Toyota T, Wei W, Adachi H. CSF GAP-43 as a biomarker of synaptic dysfunction is associated with tau pathology in Alzheimer's disease. Sci Rep 2022;12:17392. [PMID: 36253408 DOI: 10.1038/s41598-022-20324-2] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
5 Roveta F, Cermelli A, Boschi S, Ferrandes F, Grassini A, Marcinnò A, Spina M, Rubino E, Borsello T, Vercelli A, Rainero I. Synaptic Proteins as Fluid Biomarkers in Alzheimer’s Disease: A Systematic Review and Meta-Analysis. JAD 2022. [DOI: 10.3233/jad-220515] [Reference Citation Analysis]
6 Nilsson J, Cousins KAQ, Gobom J, Portelius E, Chen-Plotkin A, Shaw LM, Grossman M, Irwin DJ, Trojanowski JQ, Zetterberg H, Blennow K, Brinkmalm A. Cerebrospinal fluid biomarker panel of synaptic dysfunction in Alzheimer's disease and other neurodegenerative disorders. Alzheimers Dement 2022. [PMID: 36239248 DOI: 10.1002/alz.12809] [Reference Citation Analysis]
7 Oeckl P, Anderl-Straub S, Danek A, Diehl-Schmid J, Fassbender K, Fliessbach K, Halbgebauer S, Huppertz HJ, Jahn H, Kassubek J, Kornhuber J, Landwehrmeyer B, Lauer M, Prudlo J, Schneider A, Schroeter ML, Steinacker P, Volk AE, Wagner M, Winkelmann J, Wiltfang J, Ludolph AC, Otto M; FTLD Consortium. Relationship of serum beta-synuclein with blood biomarkers and brain atrophy. Alzheimers Dement 2022. [PMID: 36129098 DOI: 10.1002/alz.12790] [Reference Citation Analysis]
8 Dulewicz M, Kulczyńska-Przybik A, Borawska R, Słowik A, Mroczko B. Evaluation of Synaptic and Axonal Dysfunction Biomarkers in Alzheimer's Disease and Mild Cognitive Impairment Based on CSF and Bioinformatic Analysis. Int J Mol Sci 2022;23:10867. [PMID: 36142780 DOI: 10.3390/ijms231810867] [Reference Citation Analysis]
9 Massa F, Halbgebauer S, Barba L, Oeckl P, Gómez de San José N, Bauckneht M, Lanfranchi F, Vigo T, Arnaldi D, Pardini M, Morbelli S, Chincarini A, Barthel H, Otto M, Nobili F. Exploring the brain metabolic correlates of process-specific CSF biomarkers in patients with MCI due to Alzheimer's disease: preliminary data. Neurobiology of Aging 2022;117:212-21. [DOI: 10.1016/j.neurobiolaging.2022.03.019] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
10 Sogorb-esteve A, Nilsson J, Swift IJ, Heller C, Bocchetta M, Russell LL, Peakman G, Convery RS, van Swieten JC, Seelaar H, Borroni B, Galimberti D, Sanchez-valle R, Laforce R, Moreno F, Synofzik M, Graff C, Masellis M, Tartaglia MC, Rowe JB, Vandenberghe R, Finger E, Tagliavini F, Santana I, Butler CR, Ducharme S, Gerhard A, Danek A, Levin J, Otto M, Sorbi S, Le Ber I, Pasquier F, Gobom J, Brinkmalm A, Blennow K, Zetterberg H, Rohrer JD, Nelson A, Bouzigues A, Greaves CV, Cash D, Thomas DL, Todd E, Benotmane H, Nicholas J, Samra K, Shafei R, Timberlake C, Cope T, Rittman T, Benussi A, Premi E, Gasparotti R, Archetti S, Gazzina S, Cantoni V, Arighi A, Fenoglio C, Scarpini E, Fumagalli G, Borracci V, Rossi G, Giaccone G, Di Fede G, Caroppo P, Tiraboschi P, Prioni S, Redaelli V, Tang-wai D, Rogaeva E, Castelo-branco M, Freedman M, Keren R, Black S, Mitchell S, Shoesmith C, Bartha R, Rademakers R, Poos J, Papma JM, Giannini L, van Minkelen R, Pijnenburg Y, Nacmias B, Ferrari C, Polito C, Lombardi G, Bessi V, Veldsman M, Andersson C, Thonberg H, Öijerstedt L, Jelic V, Thompson P, Langheinrich T, Lladó A, Antonell A, Olives J, Balasa M, Bargalló N, Borrego-ecija S, de Mendonça A, Verdelho A, Maruta C, Ferreira CB, Miltenberger G, do Couto FS, Gabilondo A, Gorostidi A, Villanua J, Cañada M, Tainta M, Zulaica M, Barandiaran M, Alves P, Bender B, Wilke C, Graf L, Vogels A, Vandenbulcke M, Van Damme P, Bruffaerts R, Poesen K, Rosa-neto P, Gauthier S, Camuzat A, Brice A, Bertrand A, Funkiewiez A, Rinaldi D, Saracino D, Colliot O, Sayah S, Prix C, Wlasich E, Wagemann O, Loosli S, Schönecker S, Hoegen T, Lombardi J, Anderl-straub S, Rollin A, Kuchcinski G, Bertoux M, Lebouvier T, Deramecourt V, Santiago B, Duro D, Leitão MJ, Almeida MR, Tábuas-pereira M, Afonso S, on behalf of the GENetic FTD Initiative. Differential impairment of cerebrospinal fluid synaptic biomarkers in the genetic forms of frontotemporal dementia. Alz Res Therapy 2022;14:118. [DOI: 10.1186/s13195-022-01042-3] [Reference Citation Analysis]
11 Lu Y; for the Alzheimer’s Disease Neuroimaging Initiative. Cerebrospinal fluid growth-associated protein 43 levels in patients with progressive and stable mild cognitive impairment. Aging Clin Exp Res. [DOI: 10.1007/s40520-022-02202-z] [Reference Citation Analysis]
12 Barba L, Abu Rumeileh S, Bellomo G, Paolini Paoletti F, Halbgebauer S, Oeckl P, Steinacker P, Massa F, Gaetani L, Parnetti L, Otto M. Cerebrospinal fluid β-synuclein as a synaptic biomarker for preclinical Alzheimer’s disease. J Neurol Neurosurg Psychiatry 2022. [DOI: 10.1136/jnnp-2022-329124] [Reference Citation Analysis]
13 Dulewicz M, Kulczyńska-przybik A, Mroczko P, Kornhuber J, Lewczuk P, Mroczko B. Biomarkers for the Diagnosis of Alzheimer’s Disease in Clinical Practice: The Role of CSF Biomarkers during the Evolution of Diagnostic Criteria. IJMS 2022;23:8598. [DOI: 10.3390/ijms23158598] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Cummings J, Kinney J. Biomarkers for Alzheimer’s Disease: Context of Use, Qualification, and Roadmap for Clinical Implementation. Medicina 2022;58:952. [DOI: 10.3390/medicina58070952] [Reference Citation Analysis]
15 Daniilidou M, Eroli F, Alanko V, Goikolea J, Latorre-leal M, Rodriguez-rodriguez P, Griffiths WJ, Wang Y, Pacciarini M, Brinkmalm A, Zetterberg H, Blennow K, Rosenberg A, Bogdanovic N, Winblad B, Kivipelto M, Ibghi D, Cedazo-minguez A, Maioli S, Sandebring-matton A. Alzheimer’s disease biomarker profiling in a memory clinic cohort without common comorbidities.. [DOI: 10.1101/2022.06.09.495140] [Reference Citation Analysis]
16 Agnello L, Lo Sasso B, Vidali M, Scazzone C, Gambino CM, Piccoli T, Bivona G, Ciaccio AM, Giglio RV, La Bella V, Ciaccio M. Evaluation of Alpha-Synuclein Cerebrospinal Fluid Levels in Several Neurological Disorders. J Clin Med 2022;11:3139. [PMID: 35683523 DOI: 10.3390/jcm11113139] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
17 Kivisäkk P, Carlyle BC, Sweeney T, Quinn JP, Ramirez CE, Trombetta BA, Mendes M, Brock M, Rubel C, Czerkowicz J, Graham D, Arnold SE. Increased levels of the synaptic proteins PSD-95, SNAP-25, and neurogranin in the cerebrospinal fluid of patients with Alzheimer's disease. Alzheimers Res Ther 2022;14:58. [PMID: 35461266 DOI: 10.1186/s13195-022-01002-x] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
18 Zetterberg H. Biofluid-based biomarkers for Alzheimer's disease-related pathologies: An update and synthesis of the literature. Alzheimers Dement 2022. [PMID: 35213777 DOI: 10.1002/alz.12618] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
19 Camporesi E, Nilsson J, Vrillon A, Cognat E, Hourregue C, Zetterberg H, Blennow K, Becker B, Brinkmalm A, Paquet C, Brinkmalm G. Quantification of the trans-synaptic partners neurexin-neuroligin in CSF of neurodegenerative diseases by parallel reaction monitoring mass spectrometry. eBioMedicine 2022;75:103793. [DOI: 10.1016/j.ebiom.2021.103793] [Reference Citation Analysis]
20 Agnello L, Lo Sasso B, Vidali M, Scazzone C, Piccoli T, Gambino CM, Bivona G, Giglio RV, Ciaccio AM, La Bella V, Ciaccio M. Neurogranin as a Reliable Biomarker for Synaptic Dysfunction in Alzheimer's Disease. Diagnostics (Basel) 2021;11:2339. [PMID: 34943576 DOI: 10.3390/diagnostics11122339] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
21 Zhao Y, Arceneaux L, Culicchia F, Lukiw WJ. Neurofilament Light (NF-L) Chain Protein from a Highly Polymerized Structural Component of the Neuronal Cytoskeleton to a Neurodegenerative Disease Biomarker in the Periphery. HSOA J Alzheimers Neurodegener Dis 2021;7:056. [PMID: 34881359 DOI: 10.24966/AND-9608/100056] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
22 Teunissen CE, Verberk IMW, Thijssen EH, Vermunt L, Hansson O, Zetterberg H, van der Flier WM, Mielke MM, Del Campo M. Blood-based biomarkers for Alzheimer's disease: towards clinical implementation. Lancet Neurol 2022;21:66-77. [PMID: 34838239 DOI: 10.1016/S1474-4422(21)00361-6] [Cited by in Crossref: 64] [Cited by in F6Publishing: 80] [Article Influence: 64.0] [Reference Citation Analysis]
23 Chen C, Lu J, Peng W, Mak MS, Yang Y, Zhu Z, Wang S, Hou J, Zhou X, Xin W, Hu Y, Tsim KWK, Han Y, Liu Q, Pi R. Acrolein, an endogenous aldehyde induces Alzheimer's disease-like pathologies in mice: A new sporadic AD animal model. Pharmacol Res 2021;175:106003. [PMID: 34838693 DOI: 10.1016/j.phrs.2021.106003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
24 Milà-Alomà M, Brinkmalm A, Ashton NJ, Kvartsberg H, Shekari M, Operto G, Salvadó G, Falcon C, Gispert JD, Vilor-Tejedor N, Arenaza-Urquijo EM, Grau-Rivera O, Sala-Vila A, Sanchez-Benavides G, González-de-Echávarri JM, Minguillon C, Fauria K, Niñerola-Baizán A, Perissinotti A, Kollmorgen G, Suridjan I, Zetterberg H, Molinuevo JL, Blennow K, Suárez-Calvet M; ALFA Study. CSF Synaptic Biomarkers in the Preclinical Stage of Alzheimer Disease and Their Association With MRI and PET: A Cross-sectional Study. Neurology 2021;97:e2065-78. [PMID: 34556565 DOI: 10.1212/WNL.0000000000012853] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 11.0] [Reference Citation Analysis]
25 Dulewicz M, Kulczyńska-Przybik A, Słowik A, Borawska R, Mroczko B. Neurogranin and Neuronal Pentraxin Receptor as Synaptic Dysfunction Biomarkers in Alzheimer's Disease. J Clin Med 2021;10:4575. [PMID: 34640593 DOI: 10.3390/jcm10194575] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
26 Barranco N, Plá V, Alcolea D, Sánchez-Domínguez I, Fischer-Colbrie R, Ferrer I, Lleó A, Aguado F. Dense core vesicle markers in CSF and cortical tissues of patients with Alzheimer's disease. Transl Neurodegener 2021;10:37. [PMID: 34565482 DOI: 10.1186/s40035-021-00263-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
27 Viola KL, Bicca MA, Bebenek AM, Kranz DL, Nandwana V, Waters EA, Haney CR, Lee M, Gupta A, Brahmbhatt Z, Huang W, Chang T, Peck A, Valdez C, Dravid VP, Klein WL. The therapeutic and diagnostic potential of amyloid β oligomers (AβOs) selective antibodies to treat Alzheimer’s disease.. [DOI: 10.1101/2021.09.20.460817] [Reference Citation Analysis]
28 Bellingacci L, Mancini A, Gaetani L, Tozzi A, Parnetti L, Di Filippo M. Synaptic Dysfunction in Multiple Sclerosis: A Red Thread from Inflammation to Network Disconnection. Int J Mol Sci 2021;22:9753. [PMID: 34575917 DOI: 10.3390/ijms22189753] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
29 Gómez de San José N, Massa F, Halbgebauer S, Oeckl P, Steinacker P, Otto M. Neuronal pentraxins as biomarkers of synaptic activity: from physiological functions to pathological changes in neurodegeneration. J Neural Transm (Vienna) 2021. [PMID: 34460014 DOI: 10.1007/s00702-021-02411-2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
30 Hampel H, Nisticò R, Seyfried NT, Levey AI, Modeste E, Lemercier P, Baldacci F, Toschi N, Garaci F, Perry G, Emanuele E, Valenzuela PL, Lucia A, Urbani A, Sancesario GM, Mapstone M, Corbo M, Vergallo A, Lista S; Alzheimer Precision Medicine Initiative (APMI). Omics sciences for systems biology in Alzheimer's disease: State-of-the-art of the evidence. Ageing Res Rev 2021;69:101346. [PMID: 33915266 DOI: 10.1016/j.arr.2021.101346] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 23.0] [Reference Citation Analysis]
31 Angelova PR. Sources and triggers of oxidative damage in neurodegeneration. Free Radic Biol Med 2021;173:52-63. [PMID: 34224816 DOI: 10.1016/j.freeradbiomed.2021.07.003] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 11.0] [Reference Citation Analysis]
32 Malpetti M, Holland N, Jones PS, Ye R, Cope TE, Fryer TD, Hong YT, Savulich G, Rittman T, Passamonti L, Mak E, Aigbirhio FI, O'Brien JT, Rowe JB. Synaptic density in carriers of C9orf72 mutations: a [11 C]UCB-J PET study. Ann Clin Transl Neurol 2021;8:1515-23. [PMID: 34133849 DOI: 10.1002/acn3.51407] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 9.0] [Reference Citation Analysis]
33 Li L, Luo L, Chen T, Cao W, Xu X, Zhang Y, Yue P, Fan Y, Chen J, Liu M, Ma M, Tao L, Peng Y, Dong Y, Li B, Luo S, Kong J, Zhou G, Wen S, Liu A, Bao F. Proteomic Analysis of Rhesus Macaque Brain Explants Treated With Borrelia burgdorferi Identifies Host GAP-43 as a Potential Factor Associated With Lyme Neuroborreliosis. Front Cell Infect Microbiol 2021;11:647662. [PMID: 34178719 DOI: 10.3389/fcimb.2021.647662] [Reference Citation Analysis]
34 Ramos-Miguel A, Jones AA, Petyuk VA, Barakauskas VE, Barr AM, Leurgans SE, De Jager PL, Casaletto KB, Schneider JA, Bennett DA, Honer WG. Proteomic identification of select protein variants of the SNARE interactome associated with cognitive reserve in a large community sample. Acta Neuropathol 2021;141:755-70. [PMID: 33646358 DOI: 10.1007/s00401-021-02282-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
35 Nilsson J, Gobom J, Sjödin S, Brinkmalm G, Ashton NJ, Svensson J, Johansson P, Portelius E, Zetterberg H, Blennow K, Brinkmalm A. Cerebrospinal fluid biomarker panel for synaptic dysfunction in Alzheimer's disease. Alzheimers Dement (Amst) 2021;13:e12179. [PMID: 33969172 DOI: 10.1002/dad2.12179] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 11.0] [Reference Citation Analysis]
36 Zhou J, Benoit M, Sharoar MG. Recent advances in pre-clinical diagnosis of Alzheimer's disease. Metab Brain Dis 2021. [PMID: 33900524 DOI: 10.1007/s11011-021-00733-4] [Reference Citation Analysis]
37 Camporesi E, Lashley T, Gobom J, Lantero-Rodriguez J, Hansson O, Zetterberg H, Blennow K, Becker B. Neuroligin-1 in brain and CSF of neurodegenerative disorders: investigation for synaptic biomarkers. Acta Neuropathol Commun 2021;9:19. [PMID: 33522967 DOI: 10.1186/s40478-021-01119-4] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 7.0] [Reference Citation Analysis]
38 Tarawneh R. Biomarkers: Our Path Towards a Cure for Alzheimer Disease. Biomark Insights 2020;15:1177271920976367. [PMID: 33293784 DOI: 10.1177/1177271920976367] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]